Researchers at UNSW Sydney, led by Professor Tracie Barber, have made significant advancements in dialysis treatment. Collaborating with the Prince of Wales Hospital, the team has developed new methodologies for surgical trainers and ultrasound imaging to enhance the effectiveness of dialysis treatment. By altering the geometry of the surgery that opens the arterio-venous fistula, they have successfully reduced complications. Through a combination of computational models and experimental work, the researchers have identified a more optimal geometry for treatment and have introduced a new type of stent called the Abbott 'Supera'. This innovative research has already been applied to over 100 patients and the 'Supera' stent is now being used globally. The team also engages directly with patients, utilizing ultrasound scans to create personalized computational models for treatment. The research has been conducted in close collaboration with doctors, clinicians, and nurses, and the hope is that the awareness and adoption of these techniques will continue to grow [734ecaab].
In addition to this groundbreaking research, there are ongoing efforts worldwide to improve dialysis treatment and enhance patient care. From advancements in surgical techniques to the development of new medical devices, the field of dialysis is constantly evolving. Researchers and healthcare professionals are working together to find innovative solutions and improve the quality of life for patients undergoing dialysis treatment. With a focus on personalized and patient-centered care, the goal is to optimize treatment outcomes and minimize complications. Through collaboration and the application of cutting-edge technology, the future of dialysis treatment looks promising [734ecaab].
Nuwellis, Inc. has entered into a new purchase agreement with a major U.S. integrated delivery network (IDN), expanding the reach of its Aquadex therapy. The deal encompasses the network's entire 50-hospital system, aiming to enhance patient care for those suffering from conditions such as heart failure and fluid overload who do not respond to diuretics. The Aquadex SmartFlow system is designed for both adult and pediatric patients over 20 kg who experience fluid overload resistant to medical management. The company is committed to building a strong foundation of clinical and economic evidence to support the use of Aquadex in managing fluid overload. This partnership with a top US hospital network marks a significant milestone for Nuwellis and highlights the growing recognition of Aquadex as an effective solution for fluid overload management [1210afdc].